SCHEMBL84792

SCHEMBL84792

CN1CCC[C@H]1CO

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26011205 1.00
SCHEMBL30917693 1.00
SCHEMBL26011209 1.00
SCHEMBL178545 1.00
SCHEMBL1086946 1.00
Bromide SCHEMBL7595850 0.98 POLB (0.48)
Iodide SCHEMBL28525835 0.98 POLB (0.48)
SCHEMBL7328192 0.95 POLB (0.47)
Lithium Ion SCHEMBL7328185 0.93 POLB (0.45)
SCHEMBL25262256 0.93 CYP1A2 (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1788 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4511372-A1 PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB Mirati Therapeutics, Inc. (US) 2025-02-26 EP claimed
US-20240400558-A1 PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB MIRATI THERAPEUTICS, INC 2024-12-05 US claimed
CN-119072477-A Process and intermediates for the synthesis of adaglazeb 米拉蒂治疗股份有限公司 2024-12-03 CN claimed
US-20240262866-A1 METHOD FOR PREPARING ANIDULAFUNGIN DERIVATIVE JIANGSU HENGRUI PHARMACEUTICALS CO., LTD. (CN) 2024-08-08 US claimed
EP-4398897-A1 PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB Mirati Therapeutics, Inc. (US) 2024-07-17 EP claimed
CN-118317770-A Process and intermediates for the synthesis of adaglazeb 米拉蒂治疗股份有限公司 2024-07-09 CN claimed
CN-117903117-A Preparation method of KRAS G12C inhibitor divarasib 云南万宏医药科技有限公司 2024-04-19 CN claimed
EP-4349851-A1 METHOD FOR PREPARING ANIDULAFUNGIN DERIVATIVE Shanghai Senhui Medicine Co., Ltd. (CN) 2024-04-10 EP claimed
CN-117347527-A Detection method of N-methyl-L-prolyl related substances 江苏威奇达药业有限公司 2024-01-05 CN claimed
WO-2023205074-A1 PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB Mirati Therapeutics, Inc. (US) 2023-10-26 WO claimed
EP-2300470-A2 IMIDAZO[1,2-A]PYRIDINE COMPOUNDS AS GABA-A RECEPTOR MODULATORS Sepracor Inc. (US) 2011-03-30 EP claimed
WO-2009143156-A2 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SEPRACOR INC. (US) 2009-11-26 WO claimed
WO-2009030952-A2 PHENYLCARBOXAMIDE DERIVATIVES AS INHIBITORS AND EFFECTORS OF THE HEDGEHOG PATHWAY ASTRAZENECA AB (SE) 2009-03-12 WO claimed
EP-1594835-A4 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS INC (US) 2007-05-02 EP claimed
EP-1594835-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES Auspex Pharmaceuticals, Inc. (US) 2005-11-16 EP claimed
WO-2004064745-A2 METHOD OF PREPARATION OF HETEROCYCLIC MOLECULES WITH PHARMACEUTICAL PHARMACEUTICAL EXCIPIENT COSMECEUTICAL AGROCHEMICAL AND INDUSTRIAL USES AUSPEX PHARMACEUTICALS, INC. (US) 2004-08-05 WO claimed
EP-0873298-A4 CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES NPS PHARMA INC (US) 2000-05-17 EP claimed
EP-0873298-A1 CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES NPS PHARMACEUTICALS, INC. (US) 1998-10-28 EP claimed
WO-1997011934-A1 CHIRAL REDUCTIONS OF IMINES LEADING TO THE SYNTHESES OF OPTICALLY ACTIVE AMINES NPS PHARMACEUTICALS, INC. (US) 1997-04-03 WO claimed
US-4321387-A Process for the preparation of optically active nicotine analogs PHILIP MORRIS, INCORPORATED (US) 1982-03-23 US claimed